Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sanofi India's Enterprise Value is ₹74,034 Mil.
Sanofi India's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Sanofi India's EV-to-FCF for today is .
The historical rank and industry rank for Sanofi India's EV-to-FCF or its related term are showing as below:
BOM:500674'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 18.32
Current: 18.32
During the past 13 years, the highest EV-to-FCF of Sanofi India was 18.32. The lowest was 0.00. And the median was 0.00.
BOM:500674's EV-to-FCF is ranked better than 55.69% of 571
companies
in the Drug Manufacturers industry
Industry Median: 20.66
vs BOM:500674: 18.32
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sanofi India's PE Ratio (TTM) for today is calculated as:
Sanofi India's share price for today is ₹3321.00.
Sanofi India's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹134.510.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sanofi India EV-to-FCF Related Terms
Sanofi India EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sanofi India's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500674 vs LLY, JNJ, ABBV: EV-to-FCF Comparison
For the Drug Manufacturers - General subindustry, Sanofi India's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi India EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi India's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sanofi India's EV-to-FCF falls into.
Sanofi India's current Enterprise Value is ₹74,034 Mil.
Sanofi India's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Sanofi India (BOM:500674) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued.
The current stock price of ₹3,321.00 is trading 24.7% below its estimated GF Value™ of ₹4,410.30.
GuruFocus considers Sanofi India to be Modestly Undervalued.
Key valuation signals for BOM:500674:
EV-to-FCF:
GF Value™: ₹4,410.30 vs. price of ₹3,321.00 (24.7% below fair value)
No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
77GF Score
Get the complete analysis for BOM:500674
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500674 has been successfully added to your 
